XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2022
Sep. 30, 2021
Current Assets:    
Cash and cash equivalents $ 55,756,232 $ 70,072,946
Prepaid expenses 2,503,109 2,741,404
Total Current Assets 58,259,341 72,814,350
Property and equipment, net 5,562 7,023
Operating lease right-of-use asset, net 736,209 822,828
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 127,785,970 142,429,059
Current Liabilities:    
Accounts payable 1,705,128 1,277,095
Accrued expenses 1,336,629 621,960
Accrued compensation 793,250 1,906,000
Operating lease liability 186,916 177,237
Total Current Liabilities 4,021,923 3,982,292
Deferred tax liability 4,985,800 4,985,800
Operating lease liability – non current 582,302 678,234
Total Liabilities 9,590,025 9,646,326
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,129,630 and 145,979,429 shares issued and outstanding at March 31, 2022 and September 30, 2021, respectively 146,129 145,979
Additional paid-in capital 230,283,531 228,084,195
Accumulated deficit (112,834,095) (96,047,821)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 117,595,565 132,182,353
Non-controlling interest 600,380 600,380
Total Equity 118,195,945 132,782,733
Total Liabilities and Equity $ 127,785,970 $ 142,429,059